Clinical Study On The Effect Of Different Doses Of Atorvastatins On Retarding The Progression Of Vascular Cognitive Impairment

With the accelerated aging of the world’s population,cognitive decline in the elderly has become a worldwide public health problem.Alzheimer’s disease and other cognitive disorders are huge challenges in terms of size,cost,and impact.According to incomplete statistics,as of 2010,there are 35.6 million people with cognitive disorders worldwide.As the population ages,this number may increase to 66 million by 2030;and by 2050,people with dementia The rate may increase to 115 million.As the only cognitive impairment disorders that can be artificially prevented and prematurely interfered,it has attracted a great deal of attention.Atorvastatins as the most mainstream clinical application of lipid-lowering drugs in cardiovascular disease,secondary prevention and treatment has been widely used.In recent years,the pharmacological effects of statins have been gradually new research progress,in addition to reducing the role of statins,such as triglycerides,low-density lipoprotein,but also has many non-lipid-lowering effects: including anti-inflammatory effect,anti Oxidation,improving endothelium diastolic function,anti-thrombosis,stable atherosclerotic plaque,etc.From the pharmacological effects and the pathogenesis of vascular cognitive impairment,these effects of statins may be as a result of delayed vascular cognition Barriers to progress are one of the major causes of drugs.Domestic and international clinical efficacy of statins on vascular cognitive impairment and large-scale Meta analysis showed that statins can effectively alleviate the progression of the disease in patients with VCI,improve cognitive and living ability levels.AIM: To evaluate the efficacy of atorvastatin calcium in patients with vascular cognitive impairment and to evaluate the effects of different doses of atorvastatin(low dose of 10 mg / n;middle dose of 20 mg / n;high dose of Group 40 mg / n)to delay the progress of vascular cognitive impairment effect;to explore atorvastatin in the prevention and treatment of cognitive dysfunction in patients with medication to understand the high-dose statin is more effective,and enhance lipid-lowering Or high-dose atorvastatin whether there is a more wide range of applications.Methods: The Vascular Cognitive Disorders(VCI)criteria of VCI in the Dementia and Cognitive Impairment Group of Neurology Branch of Chinese Medical Association were selected among the patients admitted to the First Affiliated Hospital of Hebei North University from April 2017 to January 2018.Patients,including non-dementia vascular cognitive impairment(VCIND),vascular dementia(VD),and Alzheimer’s disease associated with vasculature(mixed dementia,MD)were enrolled in the study Patient’s general information and pre-medication MMSE simple intelligent score,Montreal Cognitive Assessment Scale Mo CA,and these patients were randomly divided into four groups,control groip;respectively,oral atorvastatin 10mg(low dose group);20mg(medium dose Group);40mg(high dose group).After 3 months of treatment,the scores of the above two scales were re-evaluated and recorded.The differences between the four different dose groups before and after treatment were compared statistically,statistically significant.The patients were given general treatment,such as hypoglycemic,regulators,quit smoking and alcohol,improve living habits and so on.Results: MMSE and Mo CA in low dose group(10mg),middle dose group(20mg)and high dose group(40mg)had significant difference before and after treatment.Atorvastatin could improve the intelligence of vascular cognitive impairment(MMSE and Mo CA scale score increased)and disease prevention have clinical effect.MMSE score difference analysis of variance,F = 1.2333,P = 0.299,P> 0.05,no significant difference between the mean;Mo CA score difference analysis of variance,F = 0.629,P = 0.537,P> 0.05,There was no significant difference in the therapeutic effect of different doses(MMSE and Mo CA score).Conclusion: Atorvastatins(statins)improve cognitive function in patients with vascular cognitive impairment at 3 months of therapy,with significant improvement in MMSE and Mo CA scores,and in three different doses of treatment(MMSE And Mo CA score increased)no statistical difference.Atorvastatin improves long-term low-dose maintenance of cognitive impairment in patients with long-term maintenance,without the need for high doses or even to achieve lipid-lowering criteria,the lack of high-dose treatment is still no evidence of no significant benefit.